ReNeuron Announces Initial Pre-clinical Data With Its ReN004 Human Stem Cell Lines For Parkinson's Disease

ReNeuron Group plc (LSE: RENE) today announces that initial in vivo testing of its ReN004 candidate stem cell lines shows them to have attributes that may favour the reversal of the neurological deficits seen in Parkinson’s disease.

Source: ReNeuron plc